HK1205252A1 - Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands - Google Patents

Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands Download PDF

Info

Publication number
HK1205252A1
HK1205252A1 HK15105467.6A HK15105467A HK1205252A1 HK 1205252 A1 HK1205252 A1 HK 1205252A1 HK 15105467 A HK15105467 A HK 15105467A HK 1205252 A1 HK1205252 A1 HK 1205252A1
Authority
HK
Hong Kong
Prior art keywords
composition
skin
substance
human
treating
Prior art date
Application number
HK15105467.6A
Other languages
English (en)
Chinese (zh)
Inventor
Hilaire Saurat Jean
Original Assignee
Thesan Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thesan Pharmaceuticals, Inc. filed Critical Thesan Pharmaceuticals, Inc.
Publication of HK1205252A1 publication Critical patent/HK1205252A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15105467.6A 2012-05-15 2013-05-15 Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands HK1205252A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12168121.7 2012-05-15
EP12168121.7A EP2664919A1 (fr) 2012-05-15 2012-05-15 Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique
PCT/IB2013/053979 WO2013171696A1 (en) 2012-05-15 2013-05-15 Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands

Publications (1)

Publication Number Publication Date
HK1205252A1 true HK1205252A1 (en) 2015-12-11

Family

ID=46801377

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105467.6A HK1205252A1 (en) 2012-05-15 2013-05-15 Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands

Country Status (19)

Country Link
US (2) US9480674B2 (enExample)
EP (2) EP2664919A1 (enExample)
JP (1) JP6254580B2 (enExample)
KR (1) KR20150022827A (enExample)
CN (1) CN104471391B (enExample)
AU (1) AU2013261093A1 (enExample)
BR (1) BR112014028307A2 (enExample)
CA (1) CA2873191A1 (enExample)
CO (1) CO7240392A2 (enExample)
HK (1) HK1205252A1 (enExample)
IL (1) IL235449A (enExample)
IN (1) IN2014DN10283A (enExample)
MX (1) MX2014013925A (enExample)
NZ (1) NZ702357A (enExample)
PH (1) PH12014502548A1 (enExample)
RU (1) RU2014150505A (enExample)
SG (1) SG11201407405VA (enExample)
WO (1) WO2013171696A1 (enExample)
ZA (1) ZA201408826B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2082736A1 (fr) 2008-01-23 2009-07-29 Jean Hilaire Saurat Composition pharmaceutique à usage topique
CN110055320A (zh) * 2012-03-17 2019-07-26 加州大学评议会 痤疮的快速诊断和个体化治疗
EP2664919A1 (fr) 2012-05-15 2013-11-20 Jean Hilaire Saurat Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique
WO2016022703A1 (en) * 2014-08-06 2016-02-11 Thesan Pharmaceuticals, Inc. Agonists of the ahr receptor pathway having sebosuppressive activity and a method for identifying said agonists
JP2016150916A (ja) * 2015-02-17 2016-08-22 株式会社マンダム 皮脂分泌抑制剤
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
EP3448398A4 (en) 2016-04-21 2019-12-18 Naked Biome, Inc. COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES
EP3522902B1 (en) 2016-10-04 2025-09-03 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Probiotic bacteria producing an ahr agonist and their use in the treatment of metabolic syndrome and obesity
EP3920908A4 (en) 2019-02-08 2022-10-05 McMaster University USE OF HYDROCARBON RECEPTOR ACTIVATORS IN THE TREATMENT OF GLUTEN-INDUCED GASTROINTESTINAL DISEASES
EP3715471A1 (en) 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
CN114144078B (zh) * 2019-07-23 2024-06-11 菲仕兰坎皮纳荷兰公司 包含乳脂肪和免疫球蛋白的营养组合物
EP3875098A1 (en) 2020-03-04 2021-09-08 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Use of coprococcus bacteria for the treatment of metabolic syndrome and inflammatory bowel diseases
US20240417400A1 (en) * 2021-10-14 2024-12-19 Galileo Biosystems, Inc. Aryl hydrocarbon receptor (ahr) modulators and therapeutic uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0614353A1 (en) * 1991-11-25 1994-09-14 Richardson-Vicks, Inc. Compositions for regulating skin wrinkles and/or skin atrophy
WO1999047118A1 (en) * 1998-03-16 1999-09-23 The Procter & Gamble Company Compositions for regulating skin appearance
CA2408152A1 (en) * 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
US6902881B2 (en) * 2000-10-13 2005-06-07 President And Fellows Of Harvard College Compounds and methods for regulating cell differentiation
US20030166583A1 (en) * 2002-02-22 2003-09-04 Oliver Yoa-Pu Hu Dermal cytochrome P450 1A inhibitors and enhancers
EP1418164A1 (en) 2002-11-07 2004-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists
FR2849597B1 (fr) * 2003-01-08 2006-12-08 Oreal Composition cosmetique pour le soin des peaux grasses, contenant un acide gras carboxylique ou l'un de ses derives
WO2006072203A1 (fr) * 2005-01-05 2006-07-13 Oliver Yoa-Pu Hu Inhibiteur ou promoteur de l’uridinediphosphate-glucuronosyltransferase2b (ugt2b)
US20060210515A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Hair growth formula
US20060210524A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Skin care composition
DE102005056890A1 (de) 2005-11-28 2007-05-31 Institut für Umweltmedizinische Forschung gGmbH Kosmetisches Verfahren zur Beeinflussung der Melaninbildung in der Haut
KR100798252B1 (ko) * 2006-01-18 2008-01-24 주식회사 엘지생활건강 ｃ-Ｋｉｔ 활성 저해제, 피부미백제 및 이를 함유하는피부미백용 조성물
DE102006011747A1 (de) * 2006-03-13 2007-09-27 Symrise Gmbh & Co. Kg Dermatologische und/oder kosmetische Zubereitungen
EP1842541A1 (en) * 2006-03-29 2007-10-10 G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg Plant components and extracts and uses thereof
EP2035430A1 (en) 2006-05-03 2009-03-18 Symrise GmbH & Co. KG 6h-benzofuro[3,2-c][1]benzopyran and [2]benzopyrano [4,3-b][1]benzopyran derivatives and wood extracts of these compounds as aryl hydrocarbon receptor (ahr) antagonists for the prevention of uv-b induced skin damage
US20080317684A1 (en) * 2006-09-06 2008-12-25 Isw Group, Inc. Topical Compositions
EP2082736A1 (fr) 2008-01-23 2009-07-29 Jean Hilaire Saurat Composition pharmaceutique à usage topique
WO2011069860A1 (en) * 2009-12-08 2011-06-16 Chr. Hansen A/S Novel use for the treatment of metabolic endotoxemia
KR20110139397A (ko) * 2010-06-23 2011-12-29 건국대학교 산학협력단 다약제 내성 저해 활성을 갖는 5,6-벤조플라본 화합물, 그의 제조 방법 및 이를 유효성분으로 포함하는 다약제 내성 저해용 조성물
CN101953838A (zh) * 2010-08-13 2011-01-26 李岱 吴茱萸次碱用于治疗银屑病的应用
EP2664919A1 (fr) 2012-05-15 2013-11-20 Jean Hilaire Saurat Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique

Also Published As

Publication number Publication date
US20150057343A1 (en) 2015-02-26
ZA201408826B (en) 2016-09-28
AU2013261093A1 (en) 2014-12-18
CN104471391A (zh) 2015-03-25
CO7240392A2 (es) 2015-04-17
KR20150022827A (ko) 2015-03-04
JP6254580B2 (ja) 2017-12-27
IN2014DN10283A (enExample) 2015-08-07
WO2013171696A1 (en) 2013-11-21
EP2850429A1 (en) 2015-03-25
PH12014502548A1 (en) 2015-01-21
BR112014028307A2 (pt) 2017-07-18
NZ702357A (en) 2016-10-28
EP2664919A1 (fr) 2013-11-20
MX2014013925A (es) 2015-05-11
CN104471391B (zh) 2016-12-07
IL235449A (en) 2017-07-31
JP2015523553A (ja) 2015-08-13
SG11201407405VA (en) 2014-12-30
CA2873191A1 (en) 2013-11-21
US20170042856A1 (en) 2017-02-16
RU2014150505A (ru) 2016-07-10
US9480674B2 (en) 2016-11-01

Similar Documents

Publication Publication Date Title
Baker et al. The mitochondrial protein OPA1 regulates the quiescent state of adult muscle stem cells
Subudhi et al. Metabolic coordination between skin epithelium and type 17 immunity sustains chronic skin inflammation
Lerman et al. Low-dose radiation augments vasculogenesis signaling through HIF-1–dependent and–independent SDF-1 induction
Ali et al. Regulatory T cells in skin facilitate epithelial stem cell differentiation
Wang et al. Basal cell carcinomas arise from hair follicle stem cells in Ptch1+/− mice
Narang et al. Efficacy and safety of topical calcipotriol in management of alopecia areata: a pilot study
Jin et al. Photobiomodulation therapy for hair regeneration: A synergetic activation of β-CATENIN in hair follicle stem cells by ROS and paracrine WNTs
Paus et al. Pathobiology of chemotherapy-induced hair loss
Miteva et al. Treatment options for alopecia: an update, looking to the future
Lohse et al. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
Gass et al. Enhancement of extinction learning attenuates ethanol-seeking behavior and alters plasticity in the prefrontal cortex
Wikramanayake et al. Targeting mitochondria in dermatological therapy: beyond oxidative damage and skin aging
Guo et al. Nicotinamide protects against skeletal muscle atrophy in streptozotocin-induced diabetic mice
Chamcheu et al. Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise
Wong et al. The exercise cytokine interleukin-15 rescues slow wound healing in aged mice
Zagni et al. PTEN mediates activation of core clock protein BMAL1 and accumulation of epidermal stem cells
Silva et al. Macrophage‐derived GPNMB accelerates skin healing
JP2015523553A5 (enExample)
Saiki et al. Aldehyde dehydrogenase 3A1 activation prevents radiation-induced xerostomia by protecting salivary stem cells from toxic aldehydes
PH12014502548A1 (en) Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands
Shibata et al. Discovery and pharmacological characterization of a new class of prolyl-tRNA synthetase inhibitor for anti-fibrosis therapy
Siitonen et al. Valproic acid combined with 13-cis retinoic acid and 1, 25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes
Escuin-Ordinas et al. Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
JP2015500820A (ja) Ｅｇｆｒ阻害の有害反応を予防または処置するための組成物
Bhardwaj et al. A novel professional‐use synergistic peel technology to reduce visible hyperpigmentation on face: Clinical evidence and mechanistic understanding by computational biology and optical biopsy